CASC3 and Miyoshi myopathy: Together, these results show the potential of combining Aplidin with GCs or Btz for the treatment of MM, as these combination therapies could prevent tumor growth whilst reducing the bone loss induced by MM cells and mitigate the adverse effects of GCs on the skeleton.